Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Keizo Takemi Tapped as New Health Minister in Cabinet Reshuffle
September 14, 2023
- MHLW Must Take Big Step on Drug Lags, Losses in FY2024 Reform: Official
September 13, 2023
- University Hospital Reform Report Finds Inadequate Review of High-Price Drug Use
September 13, 2023
- Respond to Wage Hikes for Medical Workers in FY2024 Reform: Ex-Minister
September 13, 2023
- Japan’s Envisaged IP Tax Relief Likely to Cover Drug Sales, METI Eyes FY2024 Rollout
September 13, 2023
- Moderna’s Omicron XBB.1.5 Vaccine Snags Japan Approval
September 12, 2023
- New MHLW Drug Review Chief Vows to Make Japan Attractive Place for Clinical Trials, Watching Debate on Japanese PI
September 12, 2023
- New Working Group to Propose Effective Collection and Sharing of Drug Supply Info by March-End
September 12, 2023
- Japan to End Free COVID Vaccine Program in March, Weighs NIP Inclusion
September 11, 2023
- Japan Panel OKs Use of Pfizer’s XBB.1.5 Jab for Fall Vaccination Campaign
September 11, 2023
- PMDA Reviewing Safety Risks for G-CSF Agents, Yervoy and More
September 11, 2023
- MHLW Panel OKs Changes to Guidelines for Using NDB, Anonymized Medical Data
September 11, 2023
- Japan Mulling Once-a-Year COVID Booster for Elderly in FY2024
September 8, 2023
- MHLW Moving Toward Allowing Use of Cannabis-Derived Drugs: LDP Session
September 8, 2023
- LDP Lawmakers Deplore Reported GMP Issues at Sawai
September 8, 2023
- MHLW Plans to Consolidate Class 2 and 3 OTC Drugs
September 7, 2023
- Exact Sciences’ SaMD to Assess Breast Cancer Recurrence Risk Listed on Sept. 1
September 7, 2023
- Japan Eyes AI-Driven Drug Discovery Project for Cancer, Intractable Diseases
September 7, 2023
- Japan Unveils 2nd Package Strategy for SaMD
September 7, 2023
- Japan Healthcare Spending Renews Record with 46 Trillion Yen in FY2022
September 6, 2023
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…